Acyclovir During Pregnancy: Evidence, Safety, and What Every Expectant Parent Should Understand

Acyclovir During Pregnancy: Evidence, Safety, and What Every Expectant Parent Understands

Few medical decisions carry more emotional weight than those made during pregnancy. When a pregnant patient also manages a condition like genital herpes, the questions multiply quickly: Is it safe to take antiviral medication? What happens if I have an outbreak near my due date? Could the virus harm my baby? Can I breastfeed while on acyclovir?

These are not only reasonable concerns — they are medically important ones. Fortunately, acyclovir is among the most thoroughly studied antiviral medications in the context of pregnancy, and decades of data offer meaningful reassurance alongside clear clinical guidance. This article is intended to help expectant mothers and their partners approach this topic with accurate information rather than anxiety rooted in uncertainty.

What the Research Actually Shows About Acyclovir in Pregnancy

Acyclovir has been used in pregnant patients since the 1980s, and the accumulated evidence is substantial. The Acyclovir in Pregnancy Registry, which tracked outcomes in women inadvertently or intentionally exposed to the medication during pregnancy, did not identify an elevated rate of birth defects compared to the general population. This registry, combined with subsequent observational studies and clinical experience, has informed the current consensus among major US medical organizations.

The American College of Obstetricians and Gynecologists (ACOG) recognizes acyclovir as an appropriate antiviral option during pregnancy, particularly for patients with genital herpes. It is categorized as a Pregnancy Category B medication under the older FDA classification system — meaning animal studies did not reveal fetal harm, and available human data have not demonstrated a clear risk.

No antiviral medication — or any medication — can be labeled entirely risk-free during pregnancy, and this nuance matters. However, the clinical picture for acyclovir is notably more favorable than many patients assume when they first encounter the question.

When Acyclovir Is Specifically Recommended During Pregnancy

For pregnant patients with genital herpes, antiviral therapy is not simply permitted — it is often actively recommended. Clinical guidelines support the use of suppressive acyclovir therapy beginning at 36 weeks of gestation in women with recurrent genital herpes. The purpose of this approach is to reduce the likelihood of an active outbreak at the time of delivery, which carries the greatest risk of neonatal herpes transmission.

Neonatal herpes — herpes infection in a newborn — is a serious condition that can affect the skin, eyes, mouth, or in severe cases, the central nervous system and internal organs. The risk of transmission is highest when a mother has a primary (first-time) outbreak near delivery, because she has not yet developed the antibodies that provide some degree of passive protection to the baby. For women with recurrent herpes, the absolute risk of transmission during vaginal delivery is considerably lower, but it is not zero.

Suppressive therapy with acyclovir in the final weeks of pregnancy serves two purposes: it reduces the chance of an active lesion being present at delivery, and it decreases viral shedding — the process by which the virus is released from skin and mucous membranes even without visible symptoms.

For patients experiencing a primary herpes outbreak during pregnancy, treatment with acyclovir is also recommended regardless of trimester, as the severity of symptoms and the potential for complications are greater than in recurrent episodes.

Delivery Planning and the Role of Cesarean Section

Even with suppressive therapy, the presence of active genital herpes lesions or prodromal symptoms — such as tingling or burning that precede an outbreak — at the time of labor is an indication for cesarean delivery. This recommendation exists because vaginal delivery in the presence of active viral shedding carries a meaningfully elevated risk of exposing the newborn to the virus.

Expectant mothers with a history of genital herpes should discuss delivery planning explicitly with their obstetrician well before their due date. Understanding the criteria that would lead to a cesarean delivery, and what to do if labor begins outside of normal office hours, is practical preparation that reduces the chance of a rushed or uninformed decision in the delivery room.

Acyclovir and Breastfeeding

For nursing mothers, the question of acyclovir safety during lactation is also supported by available evidence. Acyclovir does pass into breast milk in small amounts, but studies have not identified harm to nursing infants at the concentrations typically present. The American Academy of Pediatrics has historically considered acyclovir compatible with breastfeeding.

That said, patients who have active herpes lesions on or near the breast should not breastfeed from the affected area, regardless of whether they are taking antiviral medication. The concern in this scenario is direct contact transmission, not medication transfer through milk. Expressing and discarding milk from an affected breast while continuing to nurse from an unaffected breast is one option; a lactation consultant and the patient's obstetrician or pediatrician can help develop an appropriate plan.

What Partners Need to Know

A pregnant woman's partner plays a meaningful role in transmission risk management, and this dimension of the conversation is frequently overlooked. If a partner has oral or genital herpes and the pregnant woman does not, the risk of primary infection during pregnancy — particularly in the third trimester — is a genuine clinical concern. Primary infection acquired during pregnancy carries greater risks than recurrent disease managed throughout the pregnancy.

Partners who carry HSV should discuss this openly with the pregnant patient's obstetric provider. Antiviral suppressive therapy for the partner, combined with consistent use of barrier methods, can substantially reduce the probability of transmission. This is not a topic that should be navigated through assumption or avoidance.

Having the Conversation With Your Obstetric Provider

If you are pregnant and have a history of herpes simplex virus — or if you are uncertain about your status — the most important step is a direct, honest conversation with your obstetrician or midwife. Disclose your history early in prenatal care so that a management plan can be established well in advance of delivery.

Questions worth raising include:

• Should I begin suppressive acyclovir therapy, and if so, at what point in my pregnancy?
• What symptoms should prompt me to contact your office immediately?
• What is our delivery plan if I have an active outbreak or prodromal symptoms when labor begins?
• Is it safe for me to continue breastfeeding while taking acyclovir?
• Does my partner need to take any precautions?

Acyclovir has been part of obstetric care for decades, and the clinical community's familiarity with its use in this context is extensive. Patients who are well-informed and engaged in their own care are better positioned to make decisions that protect both themselves and their newborns. The goal of this resource — and of the broader mission of Zovirax Acyclovir Info — is to ensure that accurate, accessible information is available to every patient who needs it.